Genetic and phenotypic attributes of splenic marginal zone lymphomaFerdinando Bonfiglio, Estella Matutes, Alessio Bruscaggin et al.|Blood|2021Cited by 96
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patientsMatthew R. Wilson, Fiona Miall, Mayur Narkhede et al.|UCL Discovery (University College London)|2022Cited by 76
Myeloablative doses of yttrium‐90‐ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemiaAnna Guidetti, Alessandro M. Gianni, Carmelo Carlo‐Stella et al.|Cancer|2011Cited by 28
Are We Ready to Treat Diffuse Large B‐cell and High‐Grade Lymphoma According to Major Genetic Subtypes?Annalisa Chiappella, Paolo Corradini, Jennifer L. Crombie et al.|HemaSphere|2019Cited by 14
Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose <sup>90</sup>Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAMLiliana Devizzi, Alessandro M. Gianni, Anna Guidetti et al.|Journal of Clinical Oncology|2013Cited by 14